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Abstract: Previous studies report periodontitis and peri-implantitis being able to induce systemic
low-grade inflammation, which is known to be associated with increased risk for some systemic
medical disease such as cardiovascular disease. In this regard, recent studies have shown that host
modulation therapy (HMT) together with traditional mechanical and surgical treatment not only
cease the progression of periodontitis but also reduce the systemic collagenolytic biomarkers in
both oral fluids and circulation. This suggests that the corresponding adjunctive HMT-medication
could be effective in the prevention and treatment of dental peri-implantitis, as well. Furthermore,
low-cost, safe, and practical oral fluid active matrix metalloproteinase-8 (aMMP-8) lateral-flow
immunotests have been proposed as point-of-care/chair-side diagnostic tools to detect peri-implantitis
and periodontitis, and to monitor their effective resolutions, while using various therapeutic
strategies, including host modulation. This study reports the potential benefits of HMT-medication
in the prevention and treatment of dental peri-implantitis among five patients (four of five were
current/ex-smokers). In addition, the aMMP-8 point-of-care test diagnosed 20 peri-implantitis and
20 healthy controls correctly. In conclusion, this study and previous studies support the potential
effectiveness of HMT-medication(s) and point-of-care/chair-side technologies in the treatment and
diagnostics/monitoring of peri-implantitis. However, more studies are needed to further confirm this.
Keywords: peri-implantitis; periodontitis; doxycycline; inflammation; matrix metalloproteinase 8;
point-of-care testing; treatment outcome
Dental implants have become a critical strategy to improve oral function and esthetics in partially
and completely edentulous patients [1]. Increasingly, this treatment strategy has involved not only
medically healthy patients but also patients with systemic diseases such as diabetes, cardiovascular
and gastrointestinal diseases, and others [1–3]. Although in many cases implant treatments have
been described to be successful in medically compromised patients, “there is insufficient evidence to
conclude whether dental implants can remain functionally stable option” in these patients [1]. Many
studies have evaluated the success of dental implant treatments [1], but much less attention has been
paid to the risks, if any, related to proinflammatory peri-mucositis and peri-implantitis and their
potential to induce systemic low-grade inflammation. These two peri-implant diseases affect 19–65% of
patients and may have a negative impact on their health, as systemic low-grade inflammation is known
to be associated with increased risk for cardiovascular and other systemic medical diseases [4,5].
In this study, we now propose that the potential complications of peri-implant disease require
more intense treatment, not only the common disinfection and management protocols for the local
oral lesions but also all the systemically-administered host-modulation therapies (HMT) that are
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currently, and in the future, available [1,4,5]. This proposed “combination” therapy not only enhances
the efficacy of conventional dental treatments/managements for peri-implantitis but also reduces
the risks for systemic inflammation and disease(s) [4–6]. In this regard, this short communication
further studies and assesses the potential benefits of administration of HMT to the treatment of
dental implant patients (Table 1, Figure 1), and also the benefits of active matrix metalloproteinase-8
(aMMP-8)-based oral fluid point-of-care/chair-side diagnostics (Figure 2, Figure 3) to the peri-implant
disease diagnostics/monitoring. Previously, HMT administration to patients with periodontal diseases
has been studied among postmenopausal osteopenic women [5,6], and others such as patients with
cardiovascular disease [7–14]. It should be also noted that, in addition to MMP-8 (Figure 2), there are
also available other well-established “biomarkers” of both tissue destruction and systemic inflammation,
such as MMP-9, high-sensitivity C-reactive protein (hs-CRP), TNF-α, and IL-6, which are readily
available and detectable in both oral fluids and blood samples [6–15]. Additionally, other potential
biomarkers and test technologies currently exist and are under intensive research [16]. These may be
useful, as well, and should be evaluated in the future studies.
Table 1. Prevention and/or treatment of peri-implantitis by oral (systemic) host-modulation therapy
(subantimicrobial-dose doxycycline, SDD).
Patient
No. Age/Sex
No. of
Implants/Duration
Duration of
Periostat® Periostat
® Current P.I.
Status
Prevented
P.I. Reduced P.I.
(Clinical +
x-Ray
Evidence)
Case #1 73/M 5/9 years * 6 years
√
None
Case #2 50/F 1/12 years * 4 years
√
None
Case #3 84/F 2/19 years * 17 years
√
None
Case #4 65/F 4/19 years * 3 years
√
None
Case #5 62/M 1/11 years 3 years
√
None
Periostat®: Non-anti-microbial doxycycline medication: P.I.: peri-implantitis; M: male; F: female; *: current or
previous smoker. Five healthy patients (mean age = 66.8 years) with 13 implants in place for a mean of 14 years were
treated with SDD for an average of 6.6 years (J.B.). All five patients currently show no clinical or x-ray evidence of
P.I. (note that four of five P.I. patients are or were smokers*, and all are elderly, and both issues are risk-factors). In
conclusion, long-term administration of HMT (SDD) (3–17 years), adjunctive to local disinfection, may effectively
prevent and treat peri-implantitis. The study was conducted in accordance with the Declaration of Helsinki;
participants provided written informed consent, and the protocol was approved by the local ethical committee of
Stockholm Community, Sweden (2016-08-24/2016/1:8 and 2016-1-24; Dnr 2016/1410-31/1) and the Helsinki University
Central Hospital, Finland (2019-6-26; Dnr HUS/1271/2019).
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Figure 1. Subantimicrobial-dose doxycycline (SDD) administration reduces the risk of high levels of 
active MMP-8 (aMMP-8, neutrophil-type collagenase) in periodontal pockets (GCF) of post-
menopausal women with chronic periodontitis, during a 2-year double-blind placebo-controlled 
study (n = 128 subjects). Based on both “intent-to-treat” and on “per-protocol” statistical analyses, the 
odds of high aMMP-8 were significantly reduced by 60 % (p = 0.006) and 78 % (p = 0.007), respectively, 
by SDD treatment (logistic regression analysis; bar plot with error bar (95% confidence interval) 
labeled, data modified from Golub et al. [17]). Based on the recent periodontitis classification of 
Tonetti et al. [15], the patients with grade C (i.e., severe-progressive periodontitis) prior to placebo 
(only standard treatment) or SDD treatment were reduced to grade A, i.e., minimally-progressive 
disease. Measurements of aMMP-8 levels are done by Western blot (arbitrary units) (Golub et al. [17]). 
 
Figure 2. Oral fluid (saliva, mouth rinse, gingival crevicular fluid (GCF), and peri-implant sulcular 
fluid (PISF)) lateral flow aMMP-8 point-of-care/chair-side immunoassay. Lane 1, two lines indicate 
aMMP-8 levels >20 ng/mL in GCF  and a risk of progressive and active peri-implantitis before 3-
month subantimicrobial-dose doxycycline (SDD) medication as adjunctive to scaling and root 
planing. Lane 2, one line indicates aMMP-8 levels <20 ng/mL in GCF and a reduced risk of progressive 
and active peri-implantitis at 3 months after scaling and root planing treatment and adjunctive SDD. 
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Figure 1. Subantimicrobial-dose doxycycline (SDD) administration reduces the risk of high levels of
active MMP-8 (aMMP-8, neutrophil-type collagenase) in periodontal pockets (GCF) of post-menopausal
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women with chronic periodontitis, during a 2-year double-blind placebo-controlled study (n = 128
subjects). Based on both “intent-to-treat” and on “per-protocol” statistical analyses, the odds of
high aMMP-8 were significantly reduced by 60 % (p = 0.006) and 78 % (p = 0.007), respectively, by
SDD treatment (logistic regression analysis; bar plot with error bar (95% confidence interval) labeled,
data modified from Golub et al. [17]). Based on the recent periodontitis classification of Tonetti
et al. [15], the patients with grade C (i.e., severe-progressive periodontitis) prior to placebo (only
standard treatment) or SDD treatment were reduced to grade A, i.e., minimally-progressive disease.
Measurements of aMMP-8 levels are done by Western blot (arbitrary units) (Golub et al. [17]).
1 2
+ -
aMMP-8:  >20 ng/mL   <20 ng/mL
Figure 2. Oral fluid (saliva, mouth rinse, gingival crevicular fluid (GCF), and peri-implant sulcular
fluid (PISF)) lateral flow aMMP-8 point-of-care/chair-side immunoassay. Lane 1, two lines indicate
aMMP-8 levels >20 ng/mL in GCF and a risk of progressive and active peri-implantitis before 3-month
subantimicrobial-dose doxycycline (SDD) medication as adjunctive to scaling and root planing. Lane
2, one line indicates aMMP-8 levels <20 ng/mL in GCF and a reduced risk of progressive and active
peri-implantitis at 3 months after scaling and root planing treatment and adjunctive SDD.
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Figure 3. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) 
values for the ImplantSafe®/aMMP-8 point-of-care test and bleeding on probing (at least one site 
bleeding around dental implant), representing the ability of both tests to classify peri-implantitis and 
health. Peri-implantitis patients (n = 20) and healthy controls (n = 20) were characterized clinically and 
from X-rays as described earlier [10]. The study was conducted in accordance with the Declaration of 
Helsinki; participants provided written, informed consent; and the protocol was approved by the 
local ethical committee of Stockholm Community, Sweden (2016-08-24/2016/1:8 and 2016-1-24; Dnr 
2016/1410-31/1) and the Helsinki University Central Hospital, Finland (2019-6-26; Dnr 
HUS/1271/2019). 
Periodontitis and peri-implantitis-related systemic low-grade inflammation can thus also be 
readily monitored in oral fluids and serum samples, by measuring biomarkers, including MMP-8 and 
-9, pro-inflammatory mediators (TNF-α, IL-6), acute phase proteinases, and CRP, to diagnostically 
reveal the risk (Figure 1 and Figure 2) [6–16]. These biomarker measurements are indeed suitable for 
patients at evident cardiovascular risk to assess requirements for therapeutic interventions and 
medications but also for monitoring metalloproteinase inhibition with sub-antimicrobial doses of 
doxycycline to prevent acute coronary syndromes (MIDAS) and reduce harmful systemic low-grade 
inflammation [6–15]. In this way, biomarkers’ usage in monitoring diseases and their treatment have 
become clinically practical and fruitful with the current availability of point-of-care (PoC)/chair-side 
biomarker analysis of oral fluids (Figure 1, Figure 2, Figure 3) and serum [7–10]; host-modulation 
medications, including non-anti-microbial doxycycline regimen (Periostat®, now generic; and 
Oracea®), as pleiotropic MMP-inhibitors; and others, including omega-3 fatty acid derivatives (e.g., 
docosahexaenoic acid), i.e., resolvins [5,6]. Thus, recently-developed strategies of personalized use of 
HMT (Table 1), when monitored by the modern PoC/chair-side diagnostic aMMP-8-tests (Figure 1, 
Figure 2), may significantly enhance the beneficial results of both the local oral therapy (scaling and 
root planing, and oral hygiene instruction) and its effects on the systemic medical health of the 
patients (Table 1, Figure 1) [6–15]. Additional evidence of the need for modern, biologically based 
diagnostics and therapeutics to manage the oral/systemic health of patient is consistently increasing 
[5]. Such “two-pronged strategies” are at present available to the dental clinician as the result of long-
term basic and translational research [5–15]. 
The diagnostics used for periodontal and peri-implant diseases has mainly relied on the clinical 
measurements of pocket depths, attachment loss, and bleeding on probing (BOP), together with x-
ray analysis [1,4,5,7–10]. However, such diagnostic procedures can evaluate mainly past tissue 
destruction and thus do not produce any sufficient information about the ongoing disease activities 
and/or potential future risk of disease progression. Notably, the periodontal and peri-implant 
probing and BOP assessment always cause bacteremia, whereas noninvasive PoC/chair-side aMMP-
Figure 3. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC)
values for the ImplantSafe®/aMMP-8 point-of-care test and bleeding on probing (at least one site
bleeding around dental implant), representing the ability of both tests to classify peri-implantitis and
health. Peri-implantitis patients (n = 20) and healthy controls (n = 20) were characterized clinically and
from X-rays as described earlier [10]. The study was conducted in accordance with the Declaration
of Helsinki; participants provided written, informed consent; and the protocol was approved by
the local ethical committee of Stockholm Community, Sweden (2016-08-24/2016/1:8 and 2016-1-24; Dnr
2016/1410-31/1) and the Helsinki University Central Hospital, Finland (2019-6-26; Dnr HUS/1271/2019).
Periodontitis and peri-implantitis-related systemic low-grade inflammation can thus also be
readily monitored in oral fluids and serum samples, by measuring biomarkers, including MMP-8 and
-9, pro-inflammatory mediators (TNF-α, IL-6), acute phase proteinases, and CRP, to diagnostically
reveal the risk (Figures 1 and 2) [6–16]. These biomarker measurements are indeed suitable for patients
at evident cardiovascular risk to assess requirements for therapeutic interventions and medications but
also for monitoring metalloproteinase inhibition with sub-antimicrobial doses of doxycycline to prevent
acute coronary syndromes (MIDAS) and reduce harmful systemic low-grade inflammation [6–15].
In this way, biomarkers’ usage in monitoring diseases and their treatment have become clinically
practical and fruitful with the current availability of point-of-care (PoC)/chair-side biomarker analysis
of oral fluids (Figure 1, Figure 2, Figure 3) and serum [7–10]; host-modulation medications, including
non-anti-microbial doxycycline regimen (Periostat®, now generic; and Oracea®), as pleiotropic
MMP-inhibitors; and others, including omega-3 fatty acid derivatives (e.g., docosahexaenoic acid),
i.e., resolvins [5,6]. Thus, recently-developed strategies of personalized use of HMT (Table 1), when
monitored by the modern PoC/chair-side diagnostic aMMP-8-tests (Figure 1, Figure 2), may significantly
enhance the beneficial results of both the local oral therapy (scaling and root planing, and oral hygiene
instruction) and its effects on the systemic medical health of the patients (Table 1, Figure 1) [6–15].
Additional evidence of the need for modern, biologically based diagnostics and therapeutics to manage
the oral/systemic health of patient is consistently increasing [5]. Such “two-pronged strategies” are at
present available to the dental clinician as the result of long-term basic and translational research [5–15].
The diagnostics used for periodontal and peri-implant diseases has mainly relied on the clinical
measurements of pocket depths, attachment loss, and bleeding on probing (BOP), together with
x-ray analysis [1,4,5,7–10]. However, such diagnostic procedures can evaluate mainly past tissue
destruction and thus do not produce any sufficient information about the ongoing disease activities
and/or potential future risk of disease progression. Notably, the periodontal and peri-implant probing
and BOP assessment always cause bacteremia, whereas noninvasive PoC/chair-side aMMP-8 oral fluid
tests (Figure 2) never cause bacteremia and are always sterile [7–10]. Moreover, previous studies and
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the ROC analysis in Figure 3 show that PoC/chair-side aMMP-8 oral fluid tests screen on-line the tailored
dental/oral/implant health, disease, and hygiene significantly more exactly than BOP [7–10]. Therefore,
there is a clear need for the use of biomarkers to screen/diagnose sites and patients prone to these
diseases in order to do a well-timed intervention and potentially prevent peri-implant and periodontal
tissue destruction [7–10]. Collagenase-2/neutrophil-derived collagenase (also known as MMP-8) and
especially its active/activated forms [7,8], have recently been identified as major collagenolytic protease,
causing irreversible soft and hard tissue destruction during peri-implantitis and periodontitis [7–10].
In this regard, successful research has been performed in peri-implantology and periodontology by
developing the quantitative PoC/chair-side lateral flow immunoassays for active MMP-8 (aMMP-8) in
oral fluids (saliva, mouth rinse, gingival crevicular fluid [GCF], and peri-implant sulcular fluid [PISF])
as diagnostic dental peri-implant and periodontal disease biomarkers (Figure 2, Figure 3). Therefore,
the low-cost, safe, and practical oral fluid aMMP-8 lateral flow immunotests have been proposed as
a practical PoC/chair-side diagnostic tools resembling classical pregnancy tests (Figure 2) to alarm
and detect early peri-implantitis and periodontitis before clinical and x-ray manifestations [7–10], and
to monitor their effective resolutions using various therapeutic strategies including host-modulation
(Table 1, Figure 1, Figure 3).
Notably, our group also repeatedly demonstrated that treating these patients with HMT (i.e.,
non-antibiotic-dose doxycycline as a pleiotropic MMP-inhibitor) not only reduced the severity of
chronic periodontitis but also decreased the biomarkers of systemic inflammation (hs-CRP, TNF-α and
IL-6) and collagenolysis (MMP-8 and -9) in the circulation as well [5,6,11–14]. With this background
and to conclude, we now propose that animal as well as human studies be conducted to further
determine whether HMT, as an adjunct to the traditional dental implant therapies [5], reduces
the incidence and severity of peri-implantitis locally, while at the same time addressing the potential
ability of HMT to reduce the systemic inflammation (and related biomarkers levels), and, thereby,
the eventual risk for related medical conditions, including cardiovascular disease, diabetes, and stroke [5–
15]. Furthermore, there exists, and are also under development, some new and recent promising
methods, e.g., a safe, natural-product-derived anti-inflammatory and antimicrobial lingonberry mouth
rinse treatment/intervention that can be used for health promotion and disease, inflammation, and
infection prevention in the oral cavity [18]. Such management and interventions may prove to be
beneficial in the treatment of peri-implantitis and periodontitis, but more future studies are needed for
further conclusions.
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